Preclinical Characterization of a Novel Anti-Cancer PD-L1 Inhibitor RPH-120

• Main Authors: Andrey Kulikov (Author), Elena Shipaeva (Author), Anastasia Dmitrieva (Author), Vera Batrak (Author), Georgy Shipunov (Author), Colin Guy (Author), Jill Smith (Author), Ran Zhang (Author), Michael Zhang (Author), Jeff Duan (Author), Anton Chestukhin (Author), Sergei Barbashov (Author), Mikhail Samsonov (Author), Yan Lavrovsky (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

RPH-120 is a novel fully human anti-PD-L1 IgG1 monoclonal antibody with specifically designed Asn300Ala mutation in Fc fragment. Surface plasmon resonance assay showed that affinity of the RPH-120 to the dimeric form of human PD-L1-Fc fusion protein was much higher than affinity to the monomeric His...